Avidity Partners Management LP Acadia Pharmaceuticals Inc Transaction History

Avidity Partners Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $10.5 Million - $18.2 Million	588,500 New	588,500 $10.9 Million
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $6.28 Million - $8.25 Million	-300,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $4.2 Million - $6.77 Million	-250,000 Reduced 45.45%	300,000 $7 Million
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $6.15 Million - $9.66 Million	-390,000 Reduced 41.49%	550,000 $9.14 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $18.2 Million - $25.8 Million	940,000 New	940,000 $22.9 Million
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $13.2 Million - $29 Million	-527,600 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$41.04 - $56.79 $21.7 Million - $30 Million	527,600 New	527,600 $28.2 Million
Q2 2020 Aug 14, 2020	SELL	$39.26 - $52.73 $14 Million - $18.8 Million	-357,000 Closed	0 $0
Q1 2020 Jun 17, 2020	BUY	$31.65 - $46.87 $11.3 Million - $16.7 Million	357,000 New	357,000 $15.1 Million
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $1.71 Million - $2.53 Million	-54,000 Closed	0 $0
Q4 2019 Jun 17, 2020	BUY	$36.21 - $51.4 $1.96 Million - $2.78 Million	54,000 New	54,000 $2.31 Million

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.